Profit at Biogen Rises 84% on 2 Drugs
81579
BOSTON  â Biogen Idec said on Wednesday its fourth-quarter profit rose 84 percent, topping expectations, driven by increased sales of its multiple sclerosis drugs Avonex and Tysabri.
587657
Amgen Inc. AMGN.O, the world's  biggest biotechnology company, on Wednesday said quarterly net  profit fell on acquisition charges but adjusted earnings rose  21 percent on strong sales of its drugs for anemia and  arthritis.
712896
Introgen Therapeutics Inc. reported Friday that it raised an additional $7.8 million from the same European institutional investors with whom it placed shares Wednesday.
365281
Genentech Inc.  said on  Tuesday second-quarter profit rose 79 percent on demand for  cancer medicines and raised its full-year forecast, but its  stock fell as sales of colon cancer drug Avastin disappointed.
343050
The drugmaker posted third-quarter net income of $1.53 billion as revenues increased by double digits, while lower costs offset more spending on research and development.
732908
The company said fourth-quarter earnings rose 17 percent on higher sales of its Enbrel arthritis drug and Prevnar vaccine, but said generic competition would hit 2008 profit.
197756
Helped by sales of generic drugs, the pharmacy benefit manager lifted its full-year profit forecast, sending its shares higher.
283402
BASEL, Switzerland  - Profits at Roche Holding AG leapt 34 percent in 2006 on strong sales of cancer treatments Herceptin and Avastin and flu drug Tamiflu but worries over future margins hit the stock on Wednesday.
4273
The drugmaker said its third-quarter earnings more than doubled on a surge in sales of its blood thinner Plavix, and it raised its outlook for adjusted 2007 earnings.
244313
BASEL, Switzerland  - Core net profit at Roche  Holding AG rose by less than expected in 2004 despite strong  sales of cancer drugs, as products such as flu drug Tamiflu  suffered a weaker fourth quarter.
641779
Schering-Plough Corp.  on  Monday reported quarterly earnings far higher than Wall Street  expected, fueled by growing demand for its drugs against  cholesterol, arthritis, allergies and hepatitis C.
549877
The drug maker Schering-Plough Corporation said yesterday that its fourth-quarter profit surged 75 percent as strong sales of its cholesterol, arthritis and allergy medicines helped offset rising research and marketing spending.
304071
Biogen releases its third-quarter financial results.
464346
The drugmaker posted third-quarter net income of $1.53 billion as revenues increased by double digits, while lower  costs offset more spending on research and development.
356134
Merck & Co  on Monday said its  third-quarter profit rose sharply, helped by sales of its  vaccines and cholesterol drugs, and raised its 2007 profit  forecast in view of strong current trends.
63381
Biotech giant Amgen Inc. reported Thursday that its fourth-quarter profits rose, topping analysts' estimates, despite government warnings about the safety of its popular anemia drugs.
300389
Amgen  reported on Thursday that its fourth-quarter profit edged higher as cost cutting helped offset declining sales of its anemia drugs that have been hit with safety concerns and new restrictions on their use and insurance reimbursements.